About Antizyme inhibitor 1
Antizyme inhibitor 1 (AZIN1) is a protein
from Homo sapiens identified by UniProt accession
O14977, 448 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | Antizyme inhibitor 1 |
| UniProt accession | O14977 |
| Gene | AZIN1 |
| Organism | Homo sapiens |
| Length | 448 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (88)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.45
- leukocyte count · score 0.44
- high density lipoprotein cholesterol measurement · score 0.43
- alkaline phosphatase measurement · score 0.41
- mean platelet volume · score 0.41
- Immature Reticulocyte Fraction Measurement · score 0.38
- mean corpuscular volume · score 0.38
- TPE interval measurement · score 0.37
- mean corpuscular hemoglobin concentration · score 0.36
- myeloid white cell count · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14977-F1 | alphafold | PREDICTED | 88.31 | — |
Amino-acid sequence (448 residues)
MKGFIDDANY SVGLLDEGTN LGNVIDNYVY EHTLTGKNAF FVGDLGKIVK KHSQWQNVVA QIKPFYTVKC NSAPAVLEIL AALGTGFACS SKNEMALVQE LGVPPENIIY ISPCKQVSQI KYAAKVGVNI LTCDNEIELK KIARNHPNAK VLLHIATEDN IGGEEGNMKF GTTLKNCRHL LECAKELDVQ IIGVKFHVSS ACKESQVYVH ALSDARCVFD MAGEIGFTMN MLDIGGGFTG TEFQLEEVNH VISPLLDIYF PEGSGVKIIS EPGSYYVSSA FTLAVNIIAK KVVENDKFPS GVEKTGSDEP AFMYYMNDGV YGSFASKLSE DLNTIPEVHK KYKEDEPLFT SSLWGPSCDE LDQIVESCLL PELNVGDWLI FDNMGADSFH EPSAFNDFQR PAIYYMMSFS DWYEMQDAGI TSDSMMKNFF FVPSCIQLSQ EDSFSAEA
Explore Antizyme inhibitor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets